In this free webinar, explore the value of acute pain models for evaluating analgesic drug development. Attendees will learn how third molar extraction, abdominoplasty and bunionectomy can be considered the standard acute pain models for assessing the efficacy of an analgesic. The featured speakers will share how standardization of the model, including surgical technique, controlled study environment, post-op evaluation and minimizing the number of study sites will reduce variability. Attendees will learn how of the three models, bunionectomy has been employed the most and serves as the gold standard for evaluating analgesic efficacy.
TORONTO, Jan. 8, 2025 /PRNewswire-PRWeb/ -- Human pain models have been established as effective, cost-efficient tools for evaluating the efficacy of analgesic drugs. Three acute pain models have been most commonly used in recent years: bunionectomy, third molar extraction and abdominoplasty. Each of these procedures offers unique benefits but also comes with limitations.
The third molar extraction model is an inpatient procedure with post-op monitoring for 24-48 hours, high assay sensitivity and rapid enrollment. This model is commonly used for medications with low analgesic potency or as a proof-of-concept model for analgesic medications in development.
The abdominoplasty model does not require a disease or a specific diagnosis but has exhibited variability among study participants due to its episodic nature of post-surgical pain and often requires a multi-site approach to meet recruitment objectives.
While the third acute pain model, bunionectomy, will be the primary focus of this webinar, we will also discuss the critical factors that distinguish all three acute pain models, such as benefits, limitations, study timelines and cost differences between each model.
The bunionectomy model has been used for more than 25 years to evaluate oral, topical, parenteral and implantable analgesic medications. The variety of completed bunionectomy studies highlights its proven reliability with high assay sensitivity for evaluating analgesia. The post-surgery acute pain model consists of a short, standardized inpatient procedure (30-90 minutes) using different types of anesthesia with post-surgery monitoring ranging from 48 hours to 7 days, depending upon the needs of the study. The procedure involves manipulating many different tissue types, which results in moderate to severe acute pain that typically plateaus for 48-72 hours.
Despite the numerous benefits of this acute pain model, it does come with a few challenges. Adequate and consistent training to reduce variability is a key challenge that encompasses training caregivers and raters. Despite the bunion deformity being a prevalent condition across all populations, recruitment that maintains diversity within the study population can be a difficult challenge to overcome. Two challenges stand out in all three acute pain models. First, each patient has a different pain tolerance, which influences self-reported pain scales. Second, it is crucial to maintain a consistent and controlled environment to reduce variability and confounding factors.
Despite the challenges, the bunionectomy model continues to be a valuable tool with validated clinician-rated and patient-rated assessments for evaluating efficacy and safety of pain management interventions. Clinician-rated evaluations are frequently used to assess safety, such as the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) and the Columbia-Suicide Severity Rating Scale (CSSRS). Participant-rated assessments are commonly used to evaluate a medication's analgesic efficacy and include time to onset of perceived and/or meaningful relief as well as pain at rest and pain with movement rated on the Numerical Rating Scale (NRS) or the Visual Analog Scale (VAS). Given its proven track record of success and favorable experimental conditions, bunionectomy has been the most used acute pain model and is the gold standard for evaluating an analgesic's efficacy in a controlled environment.
Register for this webinar today to explore the value of acute pain models for evaluating analgesic drug development.
Join Dr. Lynn Webster, MD, Executive Vice President, Scientific Affairs, Dr. Vince Clinical Research; Dr. Ira Gottlieb, DPM, Medical Director, Chesapeake Research Group; and Rose Gerringer, Ratings Manager, Dr. Vince Clinical Research, for the live webinar on Tuesday, January 28, 2025, at 1pm EST (10am PST).
For more information, or to register for this event, visit Acute Pain Models in Drug Development.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com/
SOURCE Xtalks
Share this article